News | September 08, 2011

IABPs Do Not Reduce Infarct Size in STEMI Patients Without Cardiac Shock

September 8, 2011 – Intra-aortic balloon pump (IABP) counterpulsation prior to percutaneous coronary intervention (PCI) in patients with ST segment elevation myocardial infarction (MI) does not reduce infarct size as measured by magnetic resonance imaging (MRI), according to results from the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction (CRISP AMI) trial. The results were discussed during the recent European Society of Cardiology (ESC) meeting in Paris, France.

"Animal studies had suggested that inserting a balloon pump before opening the vessel would reduce the heart’s workload and, by doing so, could potentially reduce infarct size. However, having tested this observation in humans, we did not show similar results,” explained principal investigator Manesh Patel, M.D., from the Duke Clinical Research Institute of Duke University, Durham, N.C.

CRISP AMI was a multicenter, prospective, randomized trial in patients with acute ST segment elevation MI without shock. They were recruited within six hours of chest pain onset and planned primary PCI. Of the 337 patients enrolled, 161 were randomized to receive intra-aortic balloon counterpulsation (IABC) prior to primary PCI, and 176 to the standard-of-care (SOC), which includes primary PCI without IABC support.

The primary efficacy endpoint of the trial was infarct size measured by cardiac MRI at three to five days post-PCI. The secondary clinical endpoint was the composite of major adverse clinical events including death, reinfarction and heart failure at six months.

Results showed that mean infarct size was not significantly different between the IABC and SOC groups (42.1 vs. 37.5 percent, representing the percentage of left ventricle affected). At 30 days, major bleeding or transfusion had occurred in five (3.1 percent) of IABC patients and three (1.7 percent) of SOC patients. Major vascular complications occurred in seven IABC (4.3 percent) and two SOC (1.1 percent) patients. By six months, death had occurred in three (1.9 percent) of the IABC and nine (5.2 percent) of the SOC group.

While the study did not meet its primary endpoint, and was not powered to draw significant conclusions on clinical events, Patel says the results nevertheless offer an insight into the treatment of STEMI patients. “The most striking observation is the excellent overall outcome for the highest risk patients within the context of this trial,” he says. “The IABC group had less than 5 percent mortality, and it’s difficult to improve that. We’ve become very good at treating AMI patients.”

In the United States, acute mortality risk in AMI is between 6 percent and 15 percent; one-year mortality is estimated at 38 percent for women and 25 percent for men.

Patel adds that 15 of the patients in the SOC group crossed over to receive IABC, and five patients crossed over prior to PCI and ten patients after PCI. “While this trial shows that the routine use of IABC cannot be recommended in STEMI, physicians should be vigilant about identifying those patients who are at risk for rapid deterioration and may benefit from counterpulsation,” he says.

For more information: www.escardio.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init